ContextRisedronate, a potent bisphosphonate, has been shown to be effective in the treatment
of Paget disease of bone and other metabolic bone diseases but, to our knowledge, it …

Background Risedronate increases bone mineral density in elderly women, but whether it
prevents hip fracture is not known. Methods We studied 5445 women 70 to 79 years old who …

Background Receptor activator of nuclear factor-κB ligand (RANKL) is essential for osteoclast
differentiation, activation, and survival. The fully human monoclonal antibody denosumab (…

ContextLarge segments of the population at risk for osteoporosis and fracture have not
been evaluated, and the usefulness of peripheral measurements for short-term prediction of …

Herein we propose a new structure for poly(dopamine), a synthetic eumelanin that has
found broad utility as an antifouling agent. Commercially available 3-hydroxytyramine …

Two of the greatest challenges facing the 21st century involve providing sustainable
supplies of clean water and energy, two highly interrelated resources, at affordable costs. …

Background. To determine the effects of etidronate (a bisphosphonate that inhibits
osteoclast-mediated bone resorption) in the treatment of postmenopausal osteoporosis, we …

The World Health Organization has established a task force charged with the mission of
developing a worldwide strategy for osteoporosis management and prevention. A direct …

Background Treatment intervention thresholds for prevention of osteoporotic fractures can
be derived from reports from the World Health Organization (diagnostic criteria) and National …

All therapies currently recommended for the management of osteoporosis act mainly to
inhibit bone resorption and reduce bone remodeling. PTH and its analog, teriparatide […